Individuals with diabetes have twice the incident myocardial infarction (MI) rate as the general population, and survival rates are lower among individuals with diabetes once they have an adverse cardiovascular event.
between food intake and physical activity and it is critical to stay within daily calorie needs. Daily physical activity is important, with the appreciation that 60 minutes a day may be required to prevent weight gain and an additional 30 minutes a day may be required to sustain weight loss. Children and adolescents should be encouraged to be physically active for 60 minutes daily.
Nutritional Factors-Consumption of Fruit and Vegetables
Several studies have documented that nutritional factors play a key role in reducing CVD. Regular consumption of fruit and vegetables was associated with a 30 % relative risk reduction for myocardial infarction in the INTERHEART study. 4 These results are similar to the findings of the US Nurses Health Study, which also showed that lifestyle modification could potentially avoid more than three-quarters of the risks associated with CVD and strokes in women. 6 The Lyon Heart Study suggested that dietary modification by itself reduced the risk for coronary heart disease (CHD) by about half in patients with CVD. 7 Nutritional intake should be low in saturated fats, transfats, cholesterol, sodium, and simple sugars. Eating plenty of fruit and vegetables should be encouraged. Both high-carbohydrate and low-fat diets should be avoided because they can exacerbate insulin resistance and dyslipidemia, which can increase CVD risk. The challenge is to educate patients on the importance of substituting monounsaturated and polyunsaturated fats for saturated and transfats while also substituting high-fiber carbohydrates for low-fiber, more processed carbohydrates.
The actual distribution of macronutrients may depend on the individual's medical history and what works best in terms of weight management and palatability.
Consumption of Alcohol
Moderate alcohol consumption is associated with reduced all-cause mortality, especially CVD mortality, in the middle-aged and elderly. The reduction in CVD has been partly attributed to a more favorable lipid profile and less thrombogenic platelet function, and there is more recent evidence of favorable changes in glucose metabolism with improved insulin sensitivity and reduced risk for type 2 diabetes. 8 In nine nationally representative samples of US adults, light and moderate alcohol consumption was inversely associated with CVD mortality compared with lifetime abstainers; however, consumption above recommended limits was not associated with a decrease in CVD. 9 The benefits and risks of alcohol consumption must always be considered.
However, there is overwhelming evidence that moderate alcohol consumption is associated with reduced CVD and should not be discouraged, even in patients with type 2 diabetes. 10 Moderate drinking is defined as two standard drinks per day for a man and one standard drink per day for a woman, with one standard drink defined as 12 ounces of beer or wine cooler, five ounces of wine, or 1.5 ounces of 80-proof distilled spirits.
Smoking
Smoking is a major risk factor for CVD, with a dose-response correlation between morbidity and mortality and the number of cigarettes smoked.
Smokers are insulin-resistant and hyperinsulinemic compared with non-smokers, and these changes can lead to both dyslipidemia and hypertension. 11 One could argue that a major defect leading to increased CVD in smokers is insulin resistance and compensatory hyperinsulinemia, and that the multiple adverse consequences associated with these changes in insulin metabolism are responsible for the accelerated atherogenesis in these individuals. Several large prospective studies also suggest that smoking is linked to the development of type 2 diabetes. 12, 13 These findings show that ending smoking should be a national priority. 
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Psychosocial Factors
A large body of literature suggests that psychosocial attributes and stressful events predict the incidence of CVD. The INTERHEART study
showed that approximately 30 % of first myocardial infarctions were explained by psychosocial factors such as stress, independently of other well established CVD risk factors. 1 Another study in middle-aged women showed that depression and stress predicted the risk for developing metabolic syndrome by multiple definitions. 17 It is imperative that health professionals begin to identify and treat psychosocial factors, which have been mostly ignored as a 'non-traditional' risk factor for CVD. For over two decades, dyslipidemia therapy has focused on low-density lipoprotein cholesterol (LDL-C), which has been identified as a risk factor for CVD in retrospective, prospective, and observational studies. In addition, extensive laboratory and animal research has demonstrated the atherogenic potential of LDL-C. 19, 20 However, it is also clear that multiple studies suggest the atherogenicity of TGs and support a protective effect for HDL-C. 21 Scientific evidence points overwhelmingly to the total cholesterol (TC)/HDL-C ratio as the best predictor of CVD events. 22 The European Prospective Investigation into Cancer and Nutrition (EPIC) was a prospective population study of 21,448
Dyslipidemia
participants without diabetes or CVD between 45 and 79 years of age who were followed for 11 years. Completely independently of their LDL-C levels, participants with high non-HDL-C levels, high TG levels, or a TC/HDL-C ratio >5 were at increased CVD risk. 23 The Framingham Heart Study demonstrated a curvilinear increased incidence rate for CVD when the TC/HDL-C ratio was >5, with the CHD risk attenuating as the ratio fell below 5 (see Figure 1 ). 24 Table 1 outlines the primary Cardiovascular Risk >204/HDL-C <42 mg/dl; and in the ACCORD study there was a 31 % reduction in the primary endpoint in the subgroup that had TG >204/HDL-C <34 mg/dl. The baseline total cholesterol/HDL-C ratio in the ACCORD subgroup was 6.37 and fell to 4.53 consistent with the Framingham Heart Study curvilinear increased incidence rate for CVD when the ratio is >5
4S = Scandinavian Simvastatin Survival Study; ACCORD = Action to Control Cardiovascular Risk in Diabetes; AFCAPS = Air Force Coronary Arteriosclerosis Prevention Study; AIM-HIGH = Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes; ALLHAT = Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial; ASCOT = Anglo-Scandinavian Cardiac Outcomes Trial; BIP = Bezafibrate Infarction Prevention; CARDS = Collaborative Atorvastatin Diabetes Study; CARE = Cholesterol and Recurrent Events; FIELD = Fenofibrate Intervention and Event Lowering in Diabetes; HDL-C = high-density lipoprotein cholesterol; HHS = Helsinki Heart Study; HPS = Heart Protection Study; IDEAL = Incremental Decrease in Endpoints Through Aggressive Lipid Lowering; JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C = low-desity lipoprotein cholesterol; LIPID = The Long-Term Intervention with Pravastatin in Ischaemic Disease study; LRC-CPPT = Lipid Research Clinics Study Coronary Primary Prevention Trial; PROSPER = Prospective Study of Pravastatin in the Elderly
and attenuating once the ratio is <5. Even the 34 % reduction in primary endpoint in the Helsinki Heart Study increased to 71 % in those patients with TG >200mg/dl. All of these studies reiterate the important association between high TG and/or low HDL-C and CVD risk. MPO converts tyrosine into a stable product, 3-chlorotyrosine.
Chlorination of the phenolic ring of tyrosine may have clinical relevance because elevated 3-chlorothyrosine products have been detected in LDL-C isolated from human atherosclerotic lesions.
Furthermore, HOCL selectively targets tyrosine residues in ApoA1, which accounts for 70 % of the total protein content of HDL-C. 
Hypertension
Hypertension is the number one cause of death in the world. Diabetes increases the risk for CVD by a factor of two to three at every level of systolic blood pressure. Large-scale randomized, controlled trials have documented the benefits of blood-pressure-lowering treatment on the risk for macrovascular and microvascular complications and on survival among patients with type 2 diabetes. 29-32 Even at a systolic blood pressure of 120 mmHg, there was a significantly higher CVD mortality in patients with type 2 diabetes compared with patients who did not have diabetes. 33 Therefore, the results of ACCORD, the first randomized trial to state that a strategy of lowering blood pressure is better in patients with type 2 diabetes, came as something of a surprise. 34 Lowering blood pressure to normal levels (<120 mmHg), below current recommended levels, did not significantly reduce the risk for fatal or non-fatal CVD events compared with a blood pressure <140 mmHg. Although there were 17 % fewer cardiovascular events in the intensive group (n=208) compared with the standard group (n=237), the results did not reach statistical significance (p=0.55). However, there was a significant 40 % reduction in the risk for stroke (p=0.01).
Why did the ACCORD study not show a CVD benefit compared with other clinical trials? The study may have been underpowered. The event rate
was only half what was expected (~2 %/year), and the mean duration of 4.7 years may not have been of sufficient duration to capture a difference between the two groups. The reduced power was reflected in the relatively wide confidence interval, which does not exclude a 27 % benefit for the primary endpoint. Furthermore, even though both groups were considered to be at high risk for CVD, the aggressive treatment of other major CVD risk factors may have lowered the absolute risk to a point from which it was difficult to demonstrate further incremental benefit from more aggressive treatment of blood pressure. The TC/HDL-C ratio was 3.70 in the intensive therapy group and 3.57 in the standard therapy group, and glycated hemoglobin (HbA 1c ) was 7.6 % in both groups at the last visit. In addition, at the end of the study in both groups there were fewer patients smoking and most patients were on aspirin therapy. Based on the lack of overall clinical benefit in ACCORD, a systolic blood pressure goal of <120 mmHg may not be justified in every patient with type 2 diabetes. However, if there is a personal or family history of CVD or stroke, the patient is unable to tolerate lipid-lowering therapy and/or aspirin, and the patient has unacceptable glycemic control and smokes, a systolic blood pressure goal of <120 mmHg is recommended.
Albuminuria
Albuminuria is an independent risk factor for CVD in men and women with diabetes or hypertension, the general population, and those with established CVD. Albuminuria is an indicator of generalized endothelial injury, a hallmark of systemic atherosclerosis. A 24-hour urine albumin excretion rate ≤30 mg or an albumin/creatinine ratio (ACR) ≤30 mg/g is defined as normoalbuminuria, between 30 and 300 mg as microalbuminuria, and >300 mg as macroalbuminuria. 35 It is important to appreciate that these definitions were derived from studies that looked at the risk of a patient progressing to end-stage renal disease, and they are not applicable for the assessment of CVD and cerebrovascular disease risk. Treatments that decrease albuminuria, particularly agents that inhibit the renin-angiotensin system, reduce CVD in patients with diabetes and hypertension. Numerous studies have shown that increased albumin excretion, even at near 'normal' levels, was associated with increased CVD mortality and stroke. The
Losartan Intervention for Endpoint (LIFE) reduction in hypertension study demonstrated that to achieve an adjusted hazard ratio of 1.0 for CVD risk, the optimal ACR had to be <6.9 mg/g, which is well below the normal definition of 30 mg/g (see Figure 3) . 36 The Heart Outcomes Prevention Evaluation (HOPE) and Health Survey of Nord-Trondelag II (HUNT II) studies also showed a significant decrease in CVD mortality when ACR levels were maintained at <7.3 mg/g and <6 mg/g, respectively. 37, 38 In the HOPE study, albuminuria was the most important independent, predictive variable for the combined endpoint of CVD death, myocardial infarction, and stroke. Critical health professionals have thus begun to appreciate that albuminuria, like hypertension and dyslipidemia, is an important modifiable CVD risk factor. Urine ACR should be measured and treated if the ACR is >7 mg/g. Any albumin in the urine is abnormal, so terms such as 'micro' and 'macro' are less meaningful when it comes to CVD and should be abandoned. 
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